160 related articles for article (PubMed ID: 11392005)
21. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
Azizi M
Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
Weber MA; Giles TD
Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
[TBL] [Abstract][Full Text] [Related]
23. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
Burnier M
Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
[TBL] [Abstract][Full Text] [Related]
24. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
25. [Potential role of angiotensin receptor antagonists in renal protection].
Hayashi K; Matsuda H; Honda M; Saruta T
Nihon Rinsho; 1999 May; 57(5):1164-7. PubMed ID: 10361451
[TBL] [Abstract][Full Text] [Related]
26. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
Campbell DJ
Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S125-31. PubMed ID: 21143285
[TBL] [Abstract][Full Text] [Related]
27. [Comparison with other antihypertensive drugs, especially with ACEI].
Hiwada K
Nihon Rinsho; 1999 May; 57(5):1187-93. PubMed ID: 10361454
[TBL] [Abstract][Full Text] [Related]
28. Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist?
McInnes GT
J Hypertens Suppl; 2001 Jun; 19(1):S61-7. PubMed ID: 11451217
[TBL] [Abstract][Full Text] [Related]
29. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
Carnovali M
Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
[TBL] [Abstract][Full Text] [Related]
30. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
Ram CV
Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
[TBL] [Abstract][Full Text] [Related]
31. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
Campbell DJ
Clin Exp Pharmacol Physiol Suppl; 1996; 3():S125-31. PubMed ID: 8993851
[TBL] [Abstract][Full Text] [Related]
32. Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
Probstfield JL; O'Brien KD
Am J Cardiol; 2010 Jan; 105(1 Suppl):10A-20A. PubMed ID: 20102969
[TBL] [Abstract][Full Text] [Related]
33. [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].
Burnier M; Brunner HR
Therapie; 1998; 53(3):279-84. PubMed ID: 9773127
[TBL] [Abstract][Full Text] [Related]
34. [The therapy of arterial hypertension: a comparison between ACE inhibitors and angiotensin-II-receptor antagonists].
Rossi F; Mangrella M; Paternò E; Imperatore F; Capristo M; Imperatore C; Guarino A
Clin Ter; 1996 Oct; 147(10):475-88. PubMed ID: 9264900
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
36. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
Chiu AG; Krowiak EJ; Deeb ZE
Laryngoscope; 2001 Oct; 111(10):1729-31. PubMed ID: 11801934
[TBL] [Abstract][Full Text] [Related]
37. Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases.
Chrysant SG
Am J Cardiol; 2010 Mar; 105(6):849-52. PubMed ID: 20211330
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
[TBL] [Abstract][Full Text] [Related]
39. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
Huber K; Pachinger O; Pichler M; Klein W
Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
[TBL] [Abstract][Full Text] [Related]
40. [ACE inhibitors versus AR II antagonists. Their role in arterial hypertension].
Carmona JP
Rev Port Cardiol; 2000 Dec; 19 Suppl 2():II43-9. PubMed ID: 11301910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
